Leerink Partners, Gilead Sciences
Notable insider trades include GOOD JENNIFER L, President & CEO at Trevi Therapeutics Inc (TRVI), who sold 40277 shares on Sep 05 ’24, at $3.11 each, totaling $0.13 million. On May 29 ’24, SCIASCIA ...
Fintel on MSN7d
Leerink Partners Initiates Coverage of Voyager Therapeutics (VYGR) with Outperform RecommendationFintel reports that on October 16, 2024, Leerink Partners initiated coverage of Voyager Therapeutics (NasdaqGS:VYGR) with a ...
David Risinger, an analyst from Leerink Partners, maintained the Hold rating on AbbVie (ABBV – Research Report). The associated price ...
Veracyte (NASDAQ:VCYT – Free Report) had its price objective upped by Leerink Partners from $35.00 to $40.00 in a research report report published on Thursday morning, Benzinga reports.
Leerink Partners' affiliate, MEDACorp, announced today the launch of a new division, the Center for Pharmacoeconomics (CPE), which will be dedicated to advancing the understanding of the societal ...
Align Technology missed Wall Street estimates for third-quarter revenue on Wednesday, on lower-than-expected demand for its clear teeth aligners among younger patients.
Natera (NASDAQ:NTRA – Free Report) had its price objective hoisted by Leerink Partners from $140.00 to $150.00 in a report issued on Thursday, Benzinga reports. Leerink Partners currently has an ...
Leerink Partners analyst Faisal Khurshid said that he likes the “risk/reward” profile of Immunic’s CALLIPER trial readout, expected in April 2025. Immunic hosted a Multiple Sclerosis (MS ...
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on CYTK stock, giving a Buy rating on October 17. Roanna Ruiz’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback